Search - tctmd.com

Displaying 41 - 60 of 69

Sort: Relevancy | Date

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Presentation TCT 2017

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Presenter: Davide Capodanno, David Hildick-Smith, Marco Zimarino

October 30, 2017

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

Presentation JIM 2017

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Presenter: Dominick J. Angiolillo

February 10, 2017

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

Presenter: Jonathan M. Hill, Christoph K. Naber, Manel Sabate

November 01, 2016

Presentation TCT 2016

TCT 3: Pretreatment With P2Y12 Receptor Antagonists Is Not Associated With Improved Patency of Infarct Related-Artery in STEMI A Report from SCAAR

Presenter: Andreas Baumbach, Kurt Huber, Elmir Omerovic

October 31, 2016

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation ACC 2016

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Presenter: Dominick Angiolillo

April 03, 2016

Presentation JIM 2016

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Presenter: Alberto Menozzi

February 11, 2016

Presentation JIM 2016

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Presenter: Roxana Mehran

February 11, 2016

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White, Philippe Généreux

October 15, 2015

Presentation TCT 2015

Cangrelor II: Perspectives on in Whom to Actually Use It

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor I: Data Essentials From the Champion Trials

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Intravenous P2Y12 Inhibition: Role for Cangrelor

Presenter: George D. Dangas, Paul A. Gurbel, Robert A. Harrington

October 13, 2015

Advertisement

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

TCT 3: Pretreatment With P2Y12 Receptor Antagonists Is Not Associated With Improved Patency of Infarct Related-Artery in STEMI A Report from SCAAR

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Cangrelor IV: Transitioning to Oral ADP Antagonists

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: Perspectives on in Whom to Actually Use It

Cangrelor I: Data Essentials From the Champion Trials

Intravenous P2Y12 Inhibition: Role for Cangrelor

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content